Under the terms of the agreement, Coda will utilize its proprietary suite of technologies to create highly diverse and complex libraries of synthetic genes and proteins for Genencor. Genencor will screen these libraries for use in future research programs.
Bill Radany, CEO of Coda Genomics, said: “Coda’s capabilities in synthetic biology have been used to solve many complicated proteomic problems across agricultural and pharmaceutical R&D programs.
“Our collaboration with Genencor is a testament to our ability to apply our synthetic, proprietary technologies and methods to generate novel protein molecules to meet our client’s unique needs.”